TRK Inhibitors: A Tumor Agnostic Targeted Therapy
EP. 1: Evolution in Cancer Treatment: Tropomyosin Receptor Kinases
January 28th 2019
EP. 2: Identifying TRK-Driven Disease Amid Tumor Types
January 28th 2019
EP. 3: An Overview of the TRK Inhibition Landscape
January 28th 2019
EP. 4: Analyzing Response Rates With Larotrectinib
January 28th 2019
EP. 5: Understanding Larotrectinib's Safety Profile
January 28th 2019
EP. 6: Drawing Larotrectinib Data From Different Tumor Types
January 28th 2019
EP. 7: Patient Selection and Responses to Larotrectinib
January 28th 2019
EP. 8: Further TRK Inhibitor Development
January 28th 2019
EP. 9: Tumor Agnostic Treatments: A Changing Paradigm
January 28th 2019
EP. 10: Using Next-Gen Sequencing to Select for TRK Inhibitors
January 28th 2019
EP. 11: Current Settings for Next-Generation Sequencing
January 28th 2019
EP. 12: Selecting an Appropriate NGS Panel
January 28th 2019
EP. 13: TRK Inhibition's Future Role in Precision Medicine
January 28th 2019
